E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
In patients 65 years or older undergoing hip surgery. |
En pacientes de 65 años o más sometidos a cirugía de cadera. |
|
E.1.1.1 | Medical condition in easily understood language |
In patients 65 years or older undergoing hip surgery |
En pacientes de 65 años o más sometidos a cirugía de cadera. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051060 |
E.1.2 | Term | Hip surgery |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare the hemodynamic effects from the systolic blood pressure values ??invasive (PASI) and invasive diastolic blood pressure (PADI), arterial partial pressure of oxygen (PaO2) and arterial partial pressure of carbon dioxide (PaCO2), measured in mmHg , arterial oxygen saturation (SatO2) misobaric easured in%, pH (pH), blood hemoglobin (Hb) measured in g / dL, heart rate (HR / bpm) measured in beats per minute, oxygen saturation (SpO2 %) measured in% and hourly diuresis (D / h) measured in ml / h of isobaric levobupivacaine and isobaric bupivacaine both with fentanyl in combination, in patients 65 years or older undergoing hip surgery. |
Comparar los efectos hemodinámicos a partir de los valores de presión arterial sistólica invasiva (PASI) y de presión arterial diastólica invasiva (PADI), presión parcial arterial de oxígeno (PaO2) y presión parcial arterial de dióxido de carbono (PaCO2), medidas en mmHg, saturación arterial de oxígeno (SatO2) medida en %, pH (pH), de hemoglobina arterial (Hb) medida en g/dl, de frecuencia cardíaca (Fc/lpm) medida en latidos por minuto, de saturación parcial de oxigeno (SpO2%) medida en % y de diuresis horaria (D/h) medida en ml/h de la levobupivacaína isobárica y de la bupivacaína isobarica ambas en combinación con fentanilo, en pacientes de 65 años o más sometidos a cirugía de cadera |
|
E.2.2 | Secondary objectives of the trial |
Assess potential adverse events during surgery and 48 hours of surgery. Adverse events include adverse cardiovascular and respiratory rate from the use of levobupivacaine and bupivacaine isobariric , events related to both surgical and anesthetic techniques and exitus . |
Valorar los posibles eventos adversos durante la cirugía y a las 48 horas del acto quirúrgico. Los eventos adversos incluirían efectos adversos de tipo cardiovascular y respiratorio derivados del uso de la levobupivacaína isobárica y de la bupivacaína isobárica a, eventos relacionados con las técnicas tanto quirúrgica como anestésica y el exitus. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
men and women 65 years or older, who meet the requirements in the pre-anesthetic to be treated with spinal anesthesia with levobupivacaine and bupivacaine and fentanyl or fentanyl, fitness: from I to IV, according to the American Society of Anesthesiologists (ASA), weight> 40 kg, height> 140 cm, body mass index (BMI) <50 kg/m2, pathology cardiovascular, respiratory, renal and endocrine-metabolic to give their informed consent for participation in the study. |
hombres y mujeres de 65 años o más edad, que cumplan los requisitos en la visita pre-anestésica para ser tratados con anestesia intradural con levobupivacaína y fentanilo o bupivacaína y fentanilo, estado físico: entre I y IV, según la Asociación Americana de Anestesiología (ASA), peso > 40 kg, altura >140 cm, índice de masa corporal (IMC) <50 kg/m2, patología cardiovascular, respiratoria, renal y endocrino-metabólica que den su consentimiento informado para su participación en el estudio. |
|
E.4 | Principal exclusion criteria |
Patients with uncontrolled hypertension (systolic blood pressure values ??noninvasive> 180 mmHg and / or diastolic blood pressure noninvasively> 110mmHg), HR> 120 bpm, SpO2 <90% on arrival in the operating room and with contraindications to the realization neuraxial anesthesia (patient refusal, infection at the site of puncture or lancing different, neuromuscular degenerative disease, hypovolemia, coagulopathy or anticoagulant therapy, and morbid obesity extreme increase in intracranial pressure). |
Pacientes con hipertensión arterial no controlada (valores de presión arterial sistólica no invasiva>180 mmHg y/o de presión arterial diastólica no invasiva>110mmHg), Fc>120 lpm, SpO2<90% a la llegada a quirófano y con contraindicación a la realización de anestesia neuroaxial (rechazo del paciente, infección en el sitio de punción o distinto al de punción, enfermedad neuromuscular de tipo degenerativo, hipovolemia, coagulopatía o tratamiento anticoagulante, obesidad mórbida extrema y aumento de la presión intracraneal). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
hemodynamic variables
invasive systolic blood pressure (PASI) measured in mmHg invasive diastolic blood pressure (PADI), measured in mmHg heart rate (Fc / lpm), measured in beats per minute partial oxygen saturation (SpO2%) measured in% hourly diuresis (D / h), measured in ml / h |
Variables hemodinámicas
presión arterial sistólica invasiva (PASI), medida en mmHg presión arterial diastólica invasiva (PADI), medida en mmHg de frecuencia cardíaca (Fc/lpm), medida en latidos por minuto de saturación parcial de oxigeno (SpO2%) medida en % diuresis horaria (D/h), medida en ml/h |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
entry into the operating room, 30 minutes to the end of anesthesia |
entrada en quirófano, 30 minutos y final de la anestesia |
|
E.5.2 | Secondary end point(s) |
A. Intraoperative adverse events: 1) Cardiovascular and Respiratory: Venous air embolism (VAE), deep vein thrombosis (DVT), myocardial infarction (AMI), cerebrovascular accident (CVA), congestive heart failure (CHF), pneumonia (N), Exitus (Ex) 2) Other: Acute renal failure (ARF), vomiting (V) 3) Associated with the surgical technique: RBC transfusion (Th), plasma transfusion (TPL), nerve damage (ln), femur fracture (Fx f) 4) Associated with the anesthetic technique: paresthesia (pair), hematic puncture (ph), other
B.Postoperative adverse events (at 48 hours) 1) Cardiovascular and Respiratory: Deep vein thrombosis (DVT), myocardial infarction (AMI), cerebrovascular accident (CVA), congestive heart failure (CHF), pneumonia (N), Exitus (Ex) 2) Other: Acute renal failure (ARF), UTI (Infu), vomiting (V). 3) Associated with the surgical technique: RBC transfusion (Th), plasma transfusion (TPL), neurologic deficit (defnq), surgical wound infection (Infhq). 4) Associated with the anesthetic technique: neurological deficit (defn), postdural puncture headache (PDPH), back pain (Lumb). |
A. Eventos adversos intraoperatorios: 1)Cardiovasculares y Respiratorios: embolia gaseosa venosa (EGV), Trombosis venosa profunda (TVP), Infarto agudo de miocardio (IAM), Accidente cerebrovascular (ACV), Insuficiencia cardíaca congestiva (ICC), Neumonía (N), Exitus (Ex) 2)Otros: Insuficiencia renal aguda (IRA), Vómitos (V) 3)Asociado a la técnica quirúrgica: Transfusión hematíes (Th), Transfusión plasma (Tpl), Lesión nerviosa (ln), Fractura de fémur (Fx f) 4)Asociado a la técnica anestésica: parestesias (par), punción hemática (ph), otros
B.Eventos adversos posoperatorios (a las 48 horas) 1)Cardiovasculares y Respiratorios: Trombosis venosa profunda (TVP), Infarto agudo de miocardio (IAM), Accidente cerebrovascular (ACV), Insuficiencia cardíaca congestiva (ICC), Neumonía (N), Exitus (Ex) 2)Otros: Insuficiencia renal aguda (IRA), Infección urinaria (Infu), Vómitos(V). 3)Asociado a la técnica quirúrgica: Transfusión hematíes (Th), Transfusión plasma (Tpl), Déficit neurológico (defnq), Infección de la herida quirúrgica (Infhq). 4)Asociado a la técnica anestésica: déficit neurológico (defn), cefalea pospunción dural (CPPD), lumbalgia (lumb). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
48 hours from surgery |
48 horas desde la cirugía |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit last patient |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 19 |
E.8.9.1 | In the Member State concerned days | |